Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer
- 1 December 1981
- Vol. 48 (11), 2503-2506
- https://doi.org/10.1002/1097-0142(19811201)48:11<2503::aid-cncr2820481126>3.0.co;2-t
Abstract
Thirty-six patients with advanced breast cancer were treated with the regimen of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). Their response to the combination chemotherapy and their survival were correlated in respect to estrogen-receptor (ER) status. No patient had received any form of hormonal therapy or other chemotherapeutic agents prior to the CMF treatment. Overall response rate, both complete and partial, to chemotherapy was 60% (21/36): 88% in the ER+ group (14/16) and 35% in the ER– group (7/20). Median duration of response was 17 months in ER+ and seven months in the ER–. Median duration of survival was 27 months in ER+ patients and nine months in ER– patients after initiation of chemotherapy. These data suggest ER+ status has a beneficial effect in the responsiveness of advanced breast cancer to CMF chemotherapy and is prognostic of better survival.This publication has 9 references indexed in Scilit:
- The role of progesterone receptors in the management of advanced breast cancerCancer, 1980
- The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancerCancer, 1980
- Prognostic value of estrogen receptors in primary breast cancerCancer, 1979
- Hormone Receptors in Breast Cancer and Response to ChemotherapyNew England Journal of Medicine, 1979
- Estrogen Receptors and Responses to Chemotherapy and Hormonal Therapy in Advanced Breast CancerNew England Journal of Medicine, 1978
- Relationship between oestrogen-receptor content and histological grade in human primary breast tumoursBritish Journal of Cancer, 1978
- The Relation between Estrogen Receptors and Response Rate to Cytotoxic Chemotherapy in Metastatic Breast CancerNew England Journal of Medicine, 1978
- Oestrogen and androgen receptors in breast cancer and response to endocrine therapy.BMJ, 1975
- Radio-Ligand Binding Assay of Specific Estrogens Using a Soluble Uterine MacromoleculeJournal of Clinical Endocrinology & Metabolism, 1968